低变异等位基因频率(VAF)的TP53突变不是接受靶向治疗的慢性淋巴细胞白血病(CLL)患者的不良预后标志物 Low Variant Allele Frequency (VAF)TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Ther...
不过，Breyanzi与所有其他CAR-T疗法一样，仅在指定的治疗中心进行，因此治疗决策中应考虑其可及性。参考来源：‘U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocyt...
Chen D, Fan F, Chang AH, Su Y and Yi H (2024) Case report: Donor derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem ...
Ma, ShuoSpringer USCurrent Hematologic Malignancy ReportsBoddy CS, Ma S. Frontline therapy of CLL: evolving treatment para- digm. Curr Hematol Malig Rep. 2018;13(2):69-77.C. S. Boddy and M. Shuo, "Frontline therapy of CLL: evolving treatment paradigm," Current Hematologic Malignancy Re- ...
参考来源：‘Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor’，新闻稿。Eli Lilly；2023年...
Targeted drug therapies areoften the first-line treatment – that is, the first approach your doctor will try – for advanced or symptomatic CLL. People who relapse might get targeted therapy, too. These medicines attack specific traits on cancer cells or processes that help the cells grow, mul...
参考来源:‘U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)’,新闻稿。Bristol Myers Squibb;03/14/2024。
(3) Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. . Ibrutinib as Initial Therapy for Patients With Chronic Lymphocytic Leukemia. N Engl J Med (2015) 373:2425–37. doi: 10.1056/NEJMoa1509388 (4) Barr PM, Robak T, Owen C, et al. Sustained efficacy and deta...
Kater AP. five-year analysis of MURANO study demonstrates enduring undetectable minimal residual disease (UMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (r/r CLL) patients (pts) following fixed-duration venetoclax-rituximab (venr) therapy (tx). Presented at: the 2020 ASH ...
2.Keating MJ,O’Brien S,Albitar M,Lerner S,Plunkett W,Giles F,et al.Early results of a chemoimmunotherapy regimen of fludarabine,cyclophosphamide,and rituximab as initial therapy for chronic lymphocytic leukemia.J Clin Oncol.2005;23:4079–88. ...